Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02722408 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)
A Phase 2 study of Hypercholesteremia, sponsored by NeuroBo Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 7
- Study locations
NCT02722408 is a Phase 2 study of Hypercholesteremia that has completed, run by NeuroBo Pharmaceuticals. The registered enrollment target is 8 participants. The trial reports 7 study locations across 4 states.
The verdict
NCT02722408, a Phase 2 study of Hypercholesteremia, has completed, sponsored by NeuroBo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study was to assess the efficacy, safety, and tolerability of multiple doses of Gemcabene in patients with HoFH on stable, lipid-lowering therapy.
Conditions Studied
Interventions
- DRUG Gemcabene
Study Locations (7)
Other
- Wolfson Medical Center Internal Medicine Dept. - Holon
- Center for Research, Prevention and Treatment of Atherosclerosis - Cardiology Department of Medicine Kiryat Hadassah - Jerusalem
- Ziv Medical Center Internal Medicine Department - Safed
Quebec
- Ecogene-21 - Chicoutimi
- Montreal Heart Institute - Montreal
California
- Westside Medical Associates of Los Angeles - Beverly Hills
Ontario
- Robarts Research Institute - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-06 |
| Est. Completion | 2017-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02722408
The ClinicalTrials.gov registry entry for NCT02722408 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NeuroBo Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypercholesteremia appearing as the primary indexed condition, and to 1 intervention - of which Gemcabene is the first listed.
NCT02722408 reports 7 study locations spanning 4 distinct geographic areas - top geographies include Other, Quebec, California.
Frequently Asked Questions
What is clinical trial NCT02722408 about?
NCT02722408 is a clinical study titled "Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)". The purpose of this study was to assess the efficacy, safety, and tolerability of multiple doses of Gemcabene in patients with HoFH on stable, lipid-lowering therapy.
What is the current status of trial NCT02722408?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2016-06. Estimated completion is 2017-07.
What conditions does trial NCT02722408 study?
This clinical trial studies the following conditions: Hypercholesteremia.
What interventions are being tested in trial NCT02722408?
The interventions under investigation include: Gemcabene (DRUG).
Who is sponsoring clinical trial NCT02722408?
This trial is sponsored by NeuroBo Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02722408 being conducted?
This trial has 7 study locations across California, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.